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Whole-cell pertussis vaccine was introduced in China in 
the early 1960s. We used standard typing methods to com-
pare 96 Bordetella pertussis isolates collected before and 
after introduction of vaccination, during 1953–2005. The fol-
lowing vaccine-type alleles of the pertussis toxin (ptx) gene 
were characteristic for all prevaccination strains: ptxA2, 
ptxA3, and ptxA4. The shift to ptxA1 occurred since 1963. 
All isolates collected since 1983 contained ptxA1. Pertactin 
(prn) allele 1, prn1, was predominant, although prn2 and 
prn3 have been detected since 2000. Serotypes ﬁ  mbriae 
(Fim) 2 and Fim2,3 were found in all isolates collected be-
fore 1986. During 1997–2005, Fim3 became prevalent. Al-
though changes in electrophoresis proﬁ  les over time were 
observed, the predominant proﬁ  les during 1997–2005 re-
sembled those during the prevaccine era and those found in 
Europe before the 1990s. B. pertussis strains in China may 
differ from those in countries that have a long history of high 
vaccine coverage.
W
hooping cough (pertussis) is an acute respiratory 
infectious disease caused by the bacterium Borde-
tella pertussis. After the whole-cell pertussis (Pw) vaccines 
were introduced in many countries during 1940–1960, ill-
ness and death rates from pertussis have decreased dramati-
cally (1,2). However, pertussis remains a leading cause of 
vaccine-preventable deaths worldwide (1). A resurgence of 
pertussis has been observed in developed countries despite 
high vaccination coverage (3–9).
In the People’s Republic of China, vaccination 
against pertussis was started in the early 1960s, when 3 
doses of Pw vaccine combined with diphtheria and tet-
anus toxoids were given at 3, 4, and 5 months of age. 
In 1982, a booster dose at 18 months of age was added 
(10,11). Pw vaccines are free of charge in China. Since 
1995, acellular pertussis (Pa) vaccines containing puriﬁ  ed 
pertussis toxin (Ptx) and ﬁ  lamentous hemagglutinin have 
been also introduced. However, because Pa vaccines are 
offered at the patient’s expense, use of these vaccines has 
been minimal, especially in some resource-limited areas. 
Although since 2007 Pa vaccines have been included in 
the national expanded program on immunization, Pa and 
Pw vaccines are still used in most provinces because of 
limited availability and cost of Pa vaccines. Although the 
reported vaccination coverage for the primary 3 doses 
increased with time, before the 1980s it was low. From 
1983 through 2008, coverage ranged from 58% to 99% 
(median 93%) (Figure 1) (12).
In China, pertussis is a reportable infectious disease, 
and the number of reported cases has been decreasing (Fig-
ure 1). Since the 1990s, incidence has been <1 case/100,000 
population (12). In China, pertussis is clinically diagnosed 
by physicians; laboratory methods such as culture, PCR, 
and serologic analysis are not used for diagnosis of pertus-
sis. Therefore, the reported low incidence may be related to 
the diagnostic criteria used, suggesting substantial under-
reporting. Pertussis remains endemic to China (10–12), and 
a local outbreak was reported in April 1997.
In many countries, divergence in major antigens Ptx, 
pertactin (Prn), ﬁ  mbriae (Fim) 2, Fim3, and tracheal col-
onization factor (TcfA) between the vaccine strains and 
circulating isolates has been reported (3,4,7,9,13–16). Fur-
thermore, marked changes in B. pertussis strains have been 
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found in these countries after introduction of vaccination. 
To learn more about the B. pertussis strains circulating in 
China, we used standardized typing methods to analyze and 
compare B. pertussis isolates collected before and after the 
introduction of vaccination (17).
Materials and Methods
Bacterial Strains and Culture
We tested 3 vaccine strains and 96 clinical isolates: 25 
isolates from 1953–1958, 52 from 1963–1985, and 19 from 
1997–2005. These 3 periods were chosen according to when 
Pw vaccines were introduced (1960) and when Pa vaccines 
were added to the vaccination program (1995). Information 
on vaccine strains and clinical isolates is shown in online 
Appendix  Figure 1, www.cdc.gov/EID/content/16/11/
1695-appF1.htm) and in the online Technical Appendix 
(www.cdc.gov/EID/content/16/11/1695-Techapp.htm). 
Clinical information for patients from whom B. pertus-
sis was isolated was not available. Vaccine strains P3s10 
and CS were isolated in Beijing in 1951 (online Appendix 
Figure 1). Vaccine strain 18530 originated in the United 
States. Strains P3s10 and 18530 have been used to produce 
Pw vaccines since the early 1960s, and strain CS has been 
used to produce Pa vaccines since 1995. All B. pertussis 
isolates were conﬁ  rmed by slide agglutination with speciﬁ  c 
antiserum to B. pertussis and B. parapertussis (Murex Di-
agnostics, Dartford, UK) and by PCR according to insertion 
sequence IS481 (18). B. pertussis strains were grown on 
Bordet-Gengou agar supplemented with 15% deﬁ  brinated 
sheep blood, incubated at 37°C for 4–5 days.
Serotyping
Serotyping was performed by a microtiter plate–based 
monoclonal agglutination assay as described (17). Mono-
clonal antibodies against Fim2 (NIBSC 04/154) or Fim3 
(NIBSC 04/156) were used.
DNA Sequencing
PCR-based sequencing of 5 genes (prn, ptxA, tcfA, ﬁ  m2, 
and ﬁ  m3) was performed as described (17,19,20) with mi-
nor modiﬁ  cations. Nucleotide sequences were determined 
for the complete opening read frames of ptxA, ﬁ  m2, ﬁ  m3, 
and tcfA, and for part of prn. The same primers were used 
for ampliﬁ  cation and sequencing (Table). The sequencing 
assays were performed with an ABI Prism 3100 DNA se-
quencing system (Applied Biosystems, Foster City, CA, 
USA), and data analysis was conducted with DNASTAR 
(Madison, WI, USA) software.
Pulsed-Field Gel Electrophoresis
Pulsed-ﬁ  eld gel electrophoresis (PFGE) was performed 
as recommended (17) with minor modiﬁ  cations. Brieﬂ  y, 
after the DNA plugs were treated with 50 U of XbaI (New 
England Biolabs, Ipswich, MA, USA), the cleaved DNA 
fragments were separated by electrophoresis on a 1% aga-
rose gel by using a Chef Mapper (Bio-Rad, Hercules, CA, 
USA) with pulse times of 2.16–44.69 s for 24 h. The band 
patterns were analyzed with BioNumerics program version 
4.0 (Applied-Maths, Kortrijk, Belgium). The clustering 
method used was the unweighted pair group method with 
arithmetic mean. The Pertussis Reference Laboratory of the 
National Institute for Health and Welfare, Turku, Finland, 
used PFGE to retest 53 clinical isolates, 3 vaccine strains, 
and international reference strain 18323 (7).
The selection criteria for the 53 isolates included at 
least 1 strain for 1 unique proﬁ  le. If 2 strains had identical 
proﬁ  les, both were retested. If multiple strains represented 
the same proﬁ  le, the strains isolated in different years or dif-
ferent regions were included. For PFGE, 8 international ref-
erence strains were included. The nomenclature was based 
on the proﬁ  les already deﬁ  ned for Finland (BpFINR) and 
Sweden (BpSR) (7,21). Proﬁ  les assigned as BpCHR have 
been found only among the analyzed isolates from China. A 
2-sided Fisher exact test was used to compare frequencies of 
strain serotypes and genotypes from the 3 periods.
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Figure 1. Number of reported pertussis 
cases and pertussis vaccination coverage 
in China, 1983–2008 (12). Although 
vaccination coverage increased with 
time, it was low before the 1980s and 
only 58% in 1983.Bordetella pertussis Strains, China
Results
Fimbrial Serotypes
Vaccine strains P3s10 and CS were serotype Fim2,3, 
and vaccine strain 18530 was serotype Fim3. Among the 
clinical isolates, all 3 serotypes were found (Figure 2, panel 
A). Signiﬁ  cantly more isolates collected during 1963–1986 
were serotype Fim2 than were isolates collected during 
1953–1958 (p<0.001). Of the 19 isolates collected during 
1997–2005, we found that 15 (79%) were Fim3, 3 (16%) 
were Fim2,3, and 1 (5%) was Fim2. Signiﬁ  cantly more iso-
lates collected during 1997–2005 were serotype Fim3 than 
were isolates collected during 1953–1958 and 1963–1986 
(p<0.001 for each).
Alleles of ptxA, prn, tcfA, ﬁ  m2, and ﬁ  m3
Vaccine strains P3s10 and CS contained ptxA2/prn1/
tcfA2/ﬁ  m2–1/ﬁ  m3–1, whereas vaccine strain 18530 con-
tained ptxA3/prn1/tcfA2/ﬁ  m2–2/ﬁ  m3–1. Among the clinical 
isolates, all 4 ptxA alleles (ptxA1, ptxA2, ptxA3, and ptxA4) 
were found (Figure 2, panel B). However, the frequency of 
each allele changed over time. In the prevaccine era, 64% 
(n = 16), 24% (n = 6), and 12% (n = 3) of isolates contained 
ptxA2, ptxA3, and ptxA4, respectively. The allele ptxA1 ap-
peared in 1963 and has become predominant since then. 
After the 1980s, all isolates contained ptxA1.
Altogether 6 prn alleles (prn1, prn2, prn3, prn7, prn10, 
and prn11) were detected. The amino acid sequences in 
variable regions of the 6 alleles are shown in online Ap-
pendix Figure 2 (www.cdc.gov/EID/content/16/11/1695-
appF2.htm). Allele prn1 remained predominant at 81% 
(78/96) during the study period (Figure 2, panel C). No 
signiﬁ  cant difference was found in the frequency of ﬁ  nd-
ing prn2 and prn3 in isolates collected during 1997–2005 
than in those collected during 1953–1958 (p = 0.749) and 
1963–1986 (p = 0.0513). All 7 isolates with prn7 contained 
ptxA3, whereas all 3 isolates with prn10 contained ptxA4. 
Two isolates with prn11 contained ptxA2. All 5 isolates 
with prn2 or prn3 contained ptxA1. 
Four tcfA alleles (tcfA1, tcfA2, tcfA5, and tcfA9) were 
identiﬁ  ed. Allele tcfA2 was most common, representing 
94% (n = 90) of the isolates (online Technical Appendix). 
Also detected were 2 ﬁ  m2 (ﬁ  m2–1 and ﬁ  m2–2) and 3 ﬁ  m3 
(ﬁ  m3–1, ﬁ  m3–2, and ﬁ  m3–4) alleles. Of the 96 isolates, 90 
(94%) contained ﬁ  m2–1. All 6 isolates with ﬁ  m2–2 were 
recovered during 1953–1958. Five of the 6 isolates with 
ﬁ  m2–2 contained prn7. For the ﬁ  m3 alleles, 96% of isolates 
were ﬁ  m3–1. All 3 isolates with ﬁ  m3–2 and 1 isolate with 
ﬁ  m3–4 were recovered in 1997–2005. Identical amino acid 
sequences were found for ﬁ  m3–1 and ﬁ  m3–4, but a silent 
mutation at nt 87 was found for ﬁ  m3–4. All 3 isolates har-
boring ﬁ  m3–2 contained prn2.
PFGE Proﬁ  les
Vaccine strains P3s10 and CS had an identical proﬁ  le, 
BpCHR6, whereas vaccine strain 18530 represented Bp-
FINR13 (Figure 3). The 96 isolates produced 27 distinct 
proﬁ  les, 4 of which (BpFINR9, BpSR127, BpSR23, and 
BpSR11) have been reported in Europe. The PFGE proﬁ  les 
obtained from vaccine strain 18530 (BpFINR13) and inter-
national reference strain 18323 were not detected among 
the isolates from China. The 6 common proﬁ  les represent-
ed 70% of isolates (41 isolates with BpCHR15, 7 with Bp-
CHR6, 6 with BpCHR2, 5 with BpSR127, 5 with BpSR23, 
and 3 with BpCHR20). The PFGE proﬁ  les changed over 
time. Dendrogram analysis of the 27 proﬁ  les indicated that 
they belonged to 8 clusters. Among these clusters, 5 (clus-
ters I–IV and VII) have been reported in Europe (5,22,23).
Previous studies have shown that cluster I includes 
international reference strain 18323 and 1 clinical isolate 
(21,22). Clusters II and III include the vaccine strains and 
most strains that were circulating before the 1990s. Cluster 
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Table. Oligonucleotide primers designed and used for PCR amplification and sequencing of Bordetella pertussis, China* 
Primer Sequence,  5ƍ o 3ƍ Gene  Position 
prn-1F ATGTCTCTGTCACGCATTGTCA  prn  151–172 
prn-1R GTCCTGCATGACGACCAGCTTG  prn  1653–1632 
prn-2F CTCGAACGTCGGTGCGCTAC  prn  1479–1498 
prn-2R TCGCGTCCAGGTAGAAACCG  prn  2347–2328 
ptxA-F GGCACCATCAAAACGCAGAGGGG  ptxA  476–498 
ptxA-R ATTACCGGAGTTGGGCGGGGCTG  ptxA  1347–1325 
fim2-F ACCCATGCAAATCCCTTTCCAACGC  fim2  177–201 
fim2-R GGGGGTTGGCGATTTCCAGTTTCTC  fim2  877–853 
fim3-F ATGTCCAAGTTTTCATACCCTGCCT  fim3  336–360 
fim3-R TTCGTCTCCTGACGCCGCGTAGCGG  fim3  1033–1009 
tcfA-1F CCACATTGATTCAGGCCGCT  tcfA  251–270 
tcfA-1R CGTCCGCAGGAGACTTGGAA  tcfA  1096–1077 
tcfA-2F GACTCCGGTATGTCCGATTC  tcfA  976–995 
tcfA-2R CTACCAGGCGTAGCGATAGC  tcfA  2346–2327 
*Primer positions are listed according to the numbering of the sequences of the following GenBank accession nos.: ptxA, M13223; prn, J04560; fim2, 
Y00527; fim3, X51543; and tcfA, U16754. prn, pertactin; ptx, pertussis toxin; fim, fimbriae; tcf, tracheal colonization factor. RESEARCH
IV contains most strains currently circulating in Europe. 
Cluster VII, a new group, consists of some isolates col-
lected from Finland in 2004 (23). Of the 3 clusters identi-
ﬁ  ed in our study, 1 consisted of 4 proﬁ  les (BpCHR1–3 and 
BpFIN13). Proﬁ  le BpFINR13 was found only in pertussis 
vaccine strain 18530 (7). The strain was obtained from the 
United States and used as a vaccine strain in Finland and 
China. The second cluster contained proﬁ  les BpCHR14 
and BpCHR19, and the third contained proﬁ  les BpCHR20 
and BpCHR22.
In this study, 56 isolates tested belonged to cluster III 
(Figure 3). Cluster III contained 6 proﬁ  les (BpCHR8, Bp-
CHR15, BpCHR17, BpFINR9, BpSR23, and BpSR127) 
with a minimum of 79% overall relatedness. All isolates be-
longing to the cluster were collected during 1963–1986 and 
1997–2005. Of the 96 clinical isolates, only 2 isolates that 
belonged to cluster IV (IV-β) were identiﬁ  ed; these 2 iso-
lates had PFGE proﬁ  le BpSR11. Strains with BpSR11 were 
ﬁ  rst detected in France in 1996 (22) and have been prevalent 
in Europe since then (13). The 2 isolates with BpSR11 were 
recovered in 2000 and 2001 and contained prn2.
Discussion
Few B. pertussis isolates from China contained non-
vaccine type alleles prn2 or prn3; those that did were found 
later. In many countries, the prn1 allele is found in most 
vaccine strains and predominated before introduction of 
vaccination. However, the vaccine type strains were gradu-
ally replaced by nonvaccine type strains, mainly with al-
lele prn2, after the introduction of vaccination. The most 
prevalent type in modern isolates is prn2 (7,14,20,24). In 
Taiwan, Pw vaccines have been offered since 1954 (25). 
When 168 clinical isolates collected in Taiwan during 
1993–2004 were analyzed, prn2 strains accounted for 39% 
in 1993–1996 and increased to 90% in 1998–2004. In con-
trast to ﬁ  ndings for many countries with long histories of 
high vaccination coverage, prn2 was ﬁ  rst found in China 
in 2000. The exact reasons for the low frequency of strains 
with prn2 and their relatively late emergence in China are 
not known. One explanation might be the low vaccination 
coverage in China before the 1980s and differences in vac-
cine coverage between urban and rural areas. Another rea-
son might be the closed borders.
In Japan, divergence of Prn and Ptx between vaccine 
strains and circulating isolates (26–28) has been reported. 
Pw vaccines were introduced in Japan in 1958; the vac-
cine strain used was prn1/ptxA2. In 1971, reported vaccina-
tion coverage was 50% (8). In 1976, vaccination coverage 
dropped to only 9%, and pertussis returned. In 1981, a Pa 
vaccine containing Ptx and ﬁ  lamentous hemagglutinin was 
introduced in Japan (27). The strain used for production 
of the Pa vaccines was Tohama I (prn1/ptxA2), isolated in 
the 1950s. When 107 isolates collected from 1988 through 
2001 were studied, the nonvaccine type prn2/ptxA1 ap-
peared in 1994 and was found in 27%–42% of isolates from 
1994 through 2001 (26). A recent study reported similar 
frequency (33%) of the nonvaccine type prn2/ptxA1 in 
Japan when 60 isolates collected during 1991–2007 were 
analyzed (28).
TcfA has been shown to be crucial for B. pertussis col-
onization (29). A total of 9 tcfA alleles have been reported 
1698  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 11, November 2010
Figure 2. Frequencies of A) ﬁ  mbrial (ﬁ  m) serotypes, B) pertussis 
toxin (ptx) A alleles, and C) pertactin (prn) alleles in Bordetella 
pertussis isolates collected in China during 1953–1958, 1963–
1985, and 1997–2005.Bordetella pertussis Strains, China
(30,31), and the most common allele is tcfA2 (20,24). Our 
ﬁ  nding that 94% of isolates studied contained tcfA2 agreed 
with  ﬁ   ndings from earlier studies (20,24). Allele tcfA1 
has been described only for reference strain 18323. In our 
study, 3 clinical isolates recovered during 1953–1958 were 
found to contain tcfA1. All 3 isolates were recovered from 
the same geographic area. Allele tcfA1 contains a 75-bp 
segment not found in other tcfA variants. The strain with 
tcfA1 was postulated to be the progenitor of the strains with 
tcfA2, tcfA3, or tcfA5 (20).
Several studies have demonstrated that serotype Fim3 
is predominant in vaccinated populations, whereas sero-
types Fim2 or Fim2,3 are predominant in unvaccinated 
populations (14,32,33). In Sweden, before 1979 when Pw 
vaccines were ﬁ  rst used, 70% of circulating strains were se-
rotype Fim3 (32). During 1979–1995, when pertussis vac-
cination was stopped, Fim2 started to increase and reached 
64% in the early 1990s. In 1996, when general vaccination 
with Pa vaccines was reintroduced, prevalence of Fim2 
declined and Fim3 strains emerged rapidly. In 2002 and 
2003, Fim3 was found in 96% of fully vaccinated persons. 
In China, before introduction of vaccination, the prevalent 
serotypes were Fim2,3 and Fim2. After vaccination, the 
frequency of serotype Fim2,3 decreased and Fim2 became 
predominant. The possible explanation for the predomi-
nance of Fim2 strains after vaccination is that the 2 vac-
cine strains used in China express Fim2,3 and Fim3. The 
shift from serotype Fim2 to Fim3 was observed in 1998 
and coincided with the introduction of Pa vaccines in this 
country. Pa vaccines without ﬁ  mbrial antigens may have 
some effect on ﬁ  mbrial serotypes of circulating isolates, as 
was observed in Sweden (32); however, the exact reason 
remains to be shown.
In our study, most strains from China had different 
PFGE proﬁ  les than did those from Europe. However, many 
PFGE proﬁ  les detected among the strains from China fell 
into the same clusters as those reported in Europe (5,22). 
For example, the most common proﬁ  le, BpCHR15, fell 
into the same cluster (cluster III) as BpSR23 and BpSR127 
(14). Cluster III includes most strains circulating in Europe 
before the 1990s (5,32). In China, strains with BpCHR15 
had been prevalent during 1965–1983. Although the strains 
with BpCHR15 were recovered from several different re-
gions and over 20 years, the possibility that some strains 
were isolated during outbreaks cannot be excluded.
The major PFGE cluster circulating in Europe since the 
1990s is cluster IV (5,32). Cluster IV can be divided into 
3 subgroups (α, β, and γ), the frequency of which differs 
among countries. However, since the late 1990s in many 
countries in Europe, subgroup IV-β became more preva-
lent than the other 2 subgroups (13). In our study, only 2 
isolates with BpSR11 belonged to group IV-β, whereas no 
isolates fell into subgroups IV-α or IV-γ. This PFGE result 
correlates with genotyping results.
When we examined the association of 6 common PFGE 
proﬁ  les with different allele combinations, we found that of 
the 51 isolates with BpCHR15, BpSR23, or BpSR127, 94% 
contained ptxA1/prn1/tcfA2/ﬁ  m2–1/ﬁ  m3–1. Of the 10 iso-
lates with BpCHR6 or BpCHR20, 100% contained ptxA2/
prn1/tcfA2/ﬁ  m2–1/ﬁ  m3–1. Of the 6 isolates with BpCHR2, 
all contained ptxA3/prn7/tcfA2/ﬁ  m2–2/ﬁ  m3–1.
The emergence of B. pertussis strains carrying a novel 
allele (ptxP3) for the Ptx promoter has been recently ob-
served in countries with long histories of high vaccination 
coverage, such as the Netherlands (34). Furthermore, all 
strains from the Netherlands with BpSR11 were found to 
carry the ptxP3 allele. In our study, only 2 isolates from 
China were found to have BpSR11, suggesting that ptxP3 
strains are not common in China.
The limitations of this study include the small number 
of B. pertussis isolates collected during the study period 
and recent isolates collected mainly from Beijing and its 
surrounding area. Therefore, our data should be interpreted 
with caution, and more epidemiologic studies with a larger 
number of isolates should be conducted in this country.
In conclusion, B. pertussis strains in China may dif-
fer from those in countries with long histories of high vac-
cination coverage. Continuous monitoring of B. pertussis 
strains is needed.
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Figure 3. Dendrogram analysis of 27 pulsed-ﬁ  eld gel electrophoresis 
proﬁ  les of Bordetella pertussis isolates circulating in China during 
1953–2005. The unweighted pair group method with arithmetic 
mean with 1% band tolerance and 1% optimization settings was 
used as the clustering method. * indicates international reference 
strains (17,23); † indicates vaccine strains from China. Vaccine 
strains P3s10 and CS represent BpCHR6, and vaccine strain 
18530 represents BpFINR13.RESEARCH
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